Adage Capital Partners
LENZ

Adage Capital Partners’s LENZ Therapeutics LENZ Stock Holding History

Adage Capital Partners’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-627,618
Closed -$29.2M – 1030
2025
Q3 		$29.2M Sell
627,618
-495,120
-44% -$18.2M 0.05% 368
2025
Q2 		$32.9M Buy
1,122,738
+585,000
+109% +$15.9M 0.06% 322
2025
Q1 		$13.8M Buy
+537,738
New +$13.2M 0.03% 511
2021
Q3 		– Sell
-42,857
Closed -$9.22M – 1079
2021
Q2 		$9.22M Buy
+42,857
New +$7.46M 0.02% 719

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Adage Capital Partners's LENZ Position: Q4 2025 in Review

Adage Capital Partners sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 627,618 shares — an estimated $29.2M sold.

Adage Capital Partners first reported a position in LENZ in Q2 2021 and held it in 4 quarters. The position peaked at $32.9M in Q2 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

  • Adage Capital Partners reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Adage Capital Partners sold 627,618 LENZ Therapeutics shares in Q4 2025, an estimated $29.2M.
  • Adage Capital Partners first reported a position in LENZ Therapeutics in Q2 2021 and held it in 4 quarters.
  • Adage Capital Partners's LENZ Therapeutics position peaked at $32.9M in Q2 2025.
  • 160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Adage Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.